How – or Will – the Chevron Reversal Impact the Food Industry?
For 40 years, U.S. federal agencies have been able to make decisions and set regulation based on their interpretation of “ambiguous” statutes of laws they
Author: TAG
EFSA Report Gives International Perspective on HPAI Risk in Humans
The European Food Safety Authority published a scientific report with updates on the highly pathogenic avian influenza (HPAI) virus during the period of March to
Is the Focus on Chemicals Detracting from Microbiological Risk and Mitigation?
There has been a lot of media, social media – and, yes, TAG – coverage of the state and federal focus on chemical risks in
New FoodNet Data Shows Increased Incidence of Some Foodborne Infections
In preliminary 2023 data recently released by the CDC Foodborne Diseases Active Surveillance Network (FoodNet), Campylobacter, Cyclospora, STEC, Vibrio, and Yersinia infections were found to
Processor Cited for Seafood HACCP Violations
The failure of a seafood processor to have and implement a seafood HACCP plan can constitute a serious regulatory violation. It was exactly that for
Cottage Cheese Exemption Marks First (but likely not last) Traceability FTL Update
In the final FSMA 204 Traceability Rule, FDA included provisions for updating of the Food Traceability List (FTL) to designate new foods on the list,
CDC’s Assessment of Human Risk of Infection from H5N1
While the current assessment for the U.S. human health risk from avian influenza A (H5N1) remains low, CDC has created a “Risk by Exposure Table”
Undeclared Nuts Lead to Warning Letter
After three recalls of nut-containing products from a Michigan-based distributor within six weeks, the FDA issued a warning letter. The finding noted that food allergen
OIG: FDA Inspection and Recall Process Needs Improvement
In a case of interesting timing, less than two weeks after FDA announced the approval of its Human Foods Program reorganization plan, the OIG announced
Moderna’s mRNA-1083 Vaccine Could Combat COVID and Influenza All in One Shot
Moderna is in Phase 3 of its clinical trial for mRNA-1083, a combined COVID and influenza vaccine. The President of Moderna, Stephen Hoge, announced that
